TBK1 and obesity disorder: A recent study demonstrated that amlexanox, a dual inhibitor of TBK1 and IKKε, can reduce hepatic inflammatory reaction by inhibiting TBK1/IKKε activities, and consequently reducing obesity and insulin resistance.22 Also, loss of TBK1 kinase activity or IKKε protects mice from high fat diet‐induced metabolic dysfunction.23, 24